As of 2026-03-16, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -1.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 1,053.21 mil USD. RXRX's TTM EBITDA according to its financial statements is -572.47 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 15.5x | 14.4x |
| Forward P/E multiples | 16.1x - 21.1x | 18.8x |
| Fair Price | (16.31) - (15.72) | (16.86) |
| Upside | -577.0% - -559.6% | -593.0% |
| Date | EV/EBITDA |
| 2026-03-13 | -1.84 |
| 2026-03-12 | -1.72 |
| 2026-03-11 | -1.87 |
| 2026-03-10 | -1.86 |
| 2026-03-09 | -1.92 |
| 2026-03-06 | -1.88 |
| 2026-03-05 | -1.95 |
| 2026-03-04 | -2.04 |
| 2026-03-03 | -1.95 |
| 2026-03-02 | -2.03 |
| 2026-02-27 | -2.07 |
| 2026-02-26 | -2.16 |
| 2026-02-25 | -2.16 |
| 2026-02-24 | -1.94 |
| 2026-02-23 | -1.83 |
| 2026-02-20 | -1.84 |
| 2026-02-19 | -2.11 |
| 2026-02-18 | -1.94 |
| 2026-02-17 | -1.88 |
| 2026-02-13 | -1.90 |
| 2026-02-12 | -1.99 |
| 2026-02-11 | -2.10 |
| 2026-02-10 | -2.23 |
| 2026-02-09 | -2.35 |
| 2026-02-06 | -2.35 |
| 2026-02-05 | -1.97 |
| 2026-02-04 | -2.28 |
| 2026-02-03 | -2.46 |
| 2026-02-02 | -2.53 |
| 2026-01-30 | -2.54 |
| 2026-01-29 | -2.66 |
| 2026-01-28 | -2.79 |
| 2026-01-27 | -2.91 |
| 2026-01-26 | -2.90 |
| 2026-01-23 | -3.03 |
| 2026-01-22 | -3.24 |
| 2026-01-21 | -2.92 |
| 2026-01-20 | -2.73 |
| 2026-01-16 | -2.97 |
| 2026-01-15 | -2.95 |
| 2026-01-14 | -3.14 |
| 2026-01-13 | -2.99 |
| 2026-01-12 | -3.10 |
| 2026-01-09 | -2.97 |
| 2026-01-08 | -3.00 |
| 2026-01-07 | -3.15 |
| 2026-01-06 | -2.87 |
| 2026-01-05 | -2.70 |
| 2026-01-02 | -2.55 |
| 2025-12-31 | -2.45 |